Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza
A debate about the market-leading influenza antiviral medication, oseltamivir, which initially focused on treatment for generally mild illness, has been expanded to question the wisdom of stockpiling for use in future influenza pandemics. Although randomized controlled trial evidence confirms that oseltamivir will reduce symptom duration by 17-25 hours among otherwise healthy adolescents and adults with community-managed disease, no randomized controlled trials have examined the effectiveness...[Show more]
|Collections||ANU Research Publications|
|Source:||Emerging infectious diseases|
|Access Rights:||Open Access|
|01_Hurt_Debate_Regarding_Oseltamivir_2016.pdf||1.12 MB||Adobe PDF|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.